1 Title: SARS-CoV-2 correlates of protection from infection against

2 variants of concern

- 3 Author list: Kaiyuan Sun^{1†*}, Jinal N. Bhiman^{2,3†}, Stefano Tempia^{4,5,6}, Jackie Kleynhans^{4,5},
- Vimbai Sharon Madzorera^{2,3}, Qiniso Mkhize^{2,3}, Haajira Kaldine^{2,3}, Meredith L McMorrow^{6,8},
 Nicole Wolter^{4,7}, Jocelyn Moyes^{4,5}, Maimuna Carrim^{4,7}, Neil A Martinson^{9,10}, Kathleen Kahn¹¹
- 6 Limakatso Lebina⁹, Jacques D. du Toit¹¹, Thulisa Mkhencele⁴, Anne von Gottberg^{4,7}, Cécile
- 7 Viboud^{1‡}, Penny L. Moore^{2,3,12‡}, Cheryl Cohen^{4,5‡*} for the PHIRST-C group[#]

8 Affiliations:

- 9 ¹Division of International Epidemiology and Population Studies, Fogarty International Center, National
- 10 Institutes of Health, Bethesda, Maryland, United States of America.
- ²SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South
 Africa
- ³Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health
 Laboratory Service, Johannesburg, South Africa
- ⁴Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the
 National Health Laboratory Service, Johannesburg, South Africa.
- ⁵School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
 South Africa.
- ⁶Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of
 America.
- ⁷School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South
 Africa.
- 23 ⁸COVID-19 Response, Centers for Disease Control and Prevention, Atlanta, Georgia, United States.
- ⁹Perinatal HIV Research Unit, University of the Witwatersrand, South Africa.
- ¹⁰Johns Hopkins University Center for TB Research, Baltimore, Maryland, United States of America.
- 26 ¹¹MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public
- 27 Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- 28 ¹²Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa
- these authors contributed equally.
- 30 *‡*These authors jointly supervised this work.
- 31 *Corresponding authors. Email: kaiyuan.sun@nih.gov (KS); cherylc@nicd.ac.za (CC)
- [#]A list of authors and their affiliations appears at the end of the paper.
- 33
- 34

35 Abstract

Serum neutralizing antibodies (nAbs) induced by vaccination have been linked to protection 36 37 against symptomatic COVID-19 and severe disease. However, much less is known about the 38 efficacy of nAbs in preventing the acquisition of infection, especially in the context of natural 39 immunity and against SARS-CoV-2 immune-escape variants. In this study, we conducted 40 mediation analysis to assess serum nAbs induced by prior SARS-CoV-2 infections as potential 41 correlates of protection (CoPs) against Delta and Omicron BA.1/2 wave infections, in rural and 42 urban household cohorts in South Africa. We find that, in the Delta wave, anti-D614G nAbs 43 mediate 37% (95%CI 34% – 40%) of the total protection against infection conferred by prior 44 exposure to SARS-CoV-2, and that protection decreases with immunity waning. In contrast, anti-45 Omicron BA.1 nAbs mediate 11% (95%CI 9 – 12%) of the total protection against Omicron 46 BA.1/2 wave infections, due to Omicron's neutralization escape. These findings underscore that 47 CoPs mediated through nAbs are variant-specific, and that boosting of nAbs against circulating 48 variants might restore or confer immune protection lost due to nAb waning and/or immune 49 escape. However, the majority of immune protection against SARS-CoV-2 conferred by natural 50 infection cannot be fully explained by serum nAbs alone. Measuring these and other immune 51 markers including T-cell responses, both in the serum and in other compartments such as the 52 nasal mucosa, may be required to comprehensively understand and predict immune protection 53 against SARS-CoV-2.

55 Main text

56 The acute phase of the COVID-19 pandemic has waned with the development of SARS-CoV-2 57 population immunity in most individuals through repeated episodes of vaccination, infection, or both ^{1,2}. Owing to the unprecedented speed of SARS-CoV-2 vaccine development and 58 distribution³, considerable numbers of people were primed by vaccination, averting substantial 59 morbidity and mortality⁴. However, due to immune evasive variants, vaccine hesitancy, and lack 60 of global equity in vaccine access ^{5–7}, a substantial proportion of the world's population acquired 61 SARS-CoV-2 immunity through natural infections, especially in low- and middle-income 62 countries^{8,9}. Immune markers that reliably predict protection from infection or symptomatic 63 disease are known as "correlates of protection" (CoP). The post-pandemic era is marked by rapid 64 65 antigenic drift of Omicron subvariants leading to continued immune evasion ^{10–13}. Given this 66 complex evolutionary landscape, it remains important to identify CoPs induced by natural 67 infections and/or vaccinations against SARS-CoV-2 variants to monitor population 68 susceptibility, anticipate future waves, optimize rollout of existing vaccines, and facilitate design and approval of next generation vaccines ¹⁴. There has been significant progress in defining 69 70 serum neutralizing or binding antibodies to the spike protein as CoPs for COVID-19 vaccines, 71 although most of the data are derived from early randomized controlled trials focused on peak 72 immune response shortly after vaccination and measured against symptomatic disease caused by the ancestral strain, with updated data on variants 15-24. In comparison, little is known about 73 74 serum CoPs for infection-induced immunity and protection against acquisition of subclinical 75 infections.

76 CoPs may differ for immunity induced by infection vs. vaccination: SARS-CoV-2 infections 77 tend to induce more robust mucosal immunity despite lower serum antibody responses than intramuscularly delivered mRNA vaccines, as shown in on a mouse model ²⁵, and mucosal 78 79 immunity may play a more important role in reducing risk of infection and transmission than systemic immunity ^{26,27}. Moreover, CoPs need to be interpreted in the context of viral evolution: 80 81 in the pre-Omicron era, SAR-CoV-2 variants of concerns emerged independently from one 82 another, with the Alpha, Beta, Gamma, Delta, and Omicron variants exhibiting distinct 83 phenotypic characteristics. The Omicron variant stands out due to substantial genetic divergence 84 from earlier strains and significant immune evasion capabilities against antibody neutralization

²⁸. Equivalent antibody titers may not provide equivalent levels of protection against ancestral
 strains compared to more transmissible and immune-evasive variants like Omicron, and CoPs
 may therefore be variant-dependent. Furthermore, serum antibody titers against SARS-CoV-2
 also wane with time.

89 The challenge of defining CoP for infection induced immunity partially stems from the 90 difficulty of tracking immune exposures to SARS-CoV-2 infections, given that a significant 91 proportion of infections are asymptomatic or subclinical and cannot be fully captured by 92 traditional symptom-based surveillance protocols. The SARS-CoV-2, influenza, and respiratory 93 syncytial virus community burden, transmission dynamics, and viral interaction in South Africa (PHIRST-C) cohorts in South Africa^{29,30} overcame this challenge by implementing a rigorous 94 sampling strategy, including collection of nasal swabs twice-weekly during a period of intense 95 96 follow up, along with a total of 10 sequential blood draws spanning the D614G, Beta, Delta, and 97 Omicron BA.1/2 waves. This high-intensity sampling scheme allowed us to reconstruct the 98 cohort participants' SARS-CoV-2 infection histories with high fidelity, and to monitor infection-99 induced antibody responses over time ³⁰. Blood samples collected immediately prior to Delta and 100 Omicron waves offered a unique opportunity to investigate serum immune marker levels in close 101 proximity to the next SARS-CoV-2 exposure. Furthermore, vaccine-derived immunity remained 102 low at the onset of the Omicron BA.1/2 wave, with less than 25% of the population fully 103 immunized with Ad26.COV2.S (Janssen) and/or BNT162b2 (Pfizer BioNTech) vaccines ³¹. In 104 this study, we leveraged the PHIRST-C cohorts' unique serological and epidemiological data to 105 perform mediation analysis and assess neutralizing antibody (nAb) titers induced by prior 106 infection as CoPs against variants of concerns. Specifically, we evaluated the role of anti-D614G 107 and anti-Omicron BA.1 nAbs against the Delta and Omicron BA.1/2 variants.

108

109 **Results**

110 Cohort description and antibody titer measurements

We analyzed data from the multi-year PHIRST-C cohort study, covering the first four waves of SARS-CoV-2 infections including the Delta and Omicron BA.1/2 waves ^{29,30}. The study included a rural and an urban site in two provinces of South Africa. A total of 1200 individuals from 222 randomly selected households among the two study sites were longitudinally followed from June

115 2020 through April 2022. The study was characterized by intense nasopharyngeal swab and 116 serum sample collection from the peak of the SARS-CoV-2 D614G (1st) wave to after the peak of the Delta (3rd) wave. After this initial follow-up period, nasopharyngeal swab sample 117 118 collection stopped but serum samples continued with blood drawn immediately following the Omicron BA.1/2 (4th) wave. The timing of the serum sample collection is visualized in Fig. 1. 119 120 We previously reconstructed the detailed SARS-CoV-2 infection history of each individual in the 121 cohort up to the Omicron BA1/2 wave and demonstrated that immunity conferred by prior infection reduced the risk of reinfection ^{30,32}. In this study, we extended this work to investigate 122 123 how infection-induced neutralizing antibody (nAb) titers correlate with protection against SARS-124 CoV-2 reinfection with the Delta or Omicron BA.1/2 variants.

125 For the Delta wave, we focused on a subgroup of 797 participants from 196 households (Delta 126 wave subgroup, Table 1, Extended Data Fig. 1) who remained SARS-CoV-2 naïve or had a 127 single prior SARS-CoV-2 infection before the Delta wave (hence, removing vaccinated and 128 repeatedly infected individuals from the analysis; see Fig. 1 for the timing of the Delta wave). 129 We define prior infection as positivity on the Roche Elecsys anti-nucleocapsid assay (an assay was optimized to detect prior infection ³³), and/or rRT-PCR-positivity, at or before blood draw 5 130 131 (refer to BD5 hereafter). SARS-CoV-2 infections during the Delta wave were inferred based on 132 the anti-nucleocapsid antibody level of two pre- and one post- Delta wave serum samples, as previously described ³⁰. We focused on households with no more than six infected household 133 134 members during this wave, due to computational constraints of the transmission model (see 135 Methods Section 4 for details). Among the 797 subgroup participants, 34% (273/797) were 136 infected during the Delta wave, with attack rates of 42% (229/544) and 17% (44/253) for naïve 137 and previously infected participants, respectively.

138 To identify CoPs against the Delta variant, for the 797 participants who had been previously 139 infected, we measured their anti-D614G nAb titers (measured as the inhibitory dilution at which 140 50% neutralization is attained, referred to as ID_{50} hereafter), using the blood draw immediately 141 preceding the Delta wave (BD5). To evaluate the potential impact of antibody waning, we also 142 measured the peak nAb level for each participant (defined as the highest anti-D614G nAb titer 143 among the first 5 blood draws). We then calculated the degree to which nAbs had waned from 144 peak level to that at BD5 by calculating the difference between peak nAb titer and nAb titer at BD5 (denoted as ΔnAb^{W} hereafter). If the peak response was already below the nAb assay 145

detection threshold (which is set at 20), then ΔnAb^W was also assigned to be below the 146 147 threshold, since further titer drop was not detectable. Notably, 28% (32/113) and 58% (81/140) 148 of individuals previously infected with D614G and Beta exhibited anti-D614G nAb titers below 149 the detection threshold at BD5, respectively (Extended Data Table 1). The proportion below the 150 detection threshold was higher for individuals previously infected with the Beta variant than the 151 D614G variant, given the Beta variant has eight amino acid difference in the spike, resulting in 152 an antigenically distinct receptor binding domain compared to the D614G variant used in the 153 neutralization assay. However, more than 90% of individuals remained positive on the Roche 154 Elecsys anti-nucleocapsid assay for both prior D614G and Beta exposed individuals ³³, despite 155 low nAb titer level (Extended Data Table 1).

156 Fig. 2a shows the Delta wave participants anti-D614G nAb titers at peak and at BD5. The ID_{50} 157 geometric mean titer (GMT) was 125 (95% CI 97 - 161) at peak and waned to 85 (95% CI 69 -158 104) at BD5, representing an average 1.47 (95% CI 1.32 - 1.67) fold reduction due to waning. 159 The anti-D614G nAb titers (in log scale) at peak and at BD 5 were highly correlated (Pearson 160 correlation coefficient 0.89, p<0.0001). Comparing the nAb titers between individuals who were 161 infected during the Delta wave vs. those who were not infected, we found that the GMTs of 162 infected individuals was significantly lower than that of uninfected individuals for both anti-163 D614G nAb at peak level and at BD5 (Fig. 2b-c). In contrast, we did not find a significant difference in the degree of antibody loss due to waning (ΔnAb^W) between infected and 164 165 uninfected individuals (Fig. 2d).

166 Similarly, for the Omicron wave, we focused on a subgroup of 535 participants from 184 167 households who had only one prior SARS-CoV-2 infection (vaccinated and repeatedly infected 168 individuals were removed from the analysis) or remained naïve just before the Omicron wave 169 (see Table 1 and Extended Data Fig. 2 for a description of participants and Fig. 1 for the timing 170 of the Omicron wave). Prior SARS-CoV-2 infection was ascertained in a similar fashion as for 171 the Delta wave (i.e., positivity by anti-nucleocapsid assay and/or rRT-PCR for the first 8 blood 172 draws). Infections during the Omicron wave were inferred based on the anti-nucleocapsid 173 antibody level of two pre- and one post- Omicron wave serum samples, as previously described 174 ³⁰. Two thirds, or 67% (359/535), of participants included in the Omicron BA.1/2 wave analysis

were infected by these variants, with attack rates of 77% (149/193) and 61% (210/342) for naïve
and previously infected individuals, respectively.

177 To evaluate nAbs as CoP in the context of Omicron's extensive immune escape, we measured 178 both the anti-D614G nAb titers and anti-Omicron BA.1 nAb titers for serum samples collected at 179 blood draw 8 (the blood draw taken shortly before the onset of the Omicron wave, referred to as 180 BD8 hereafter). Given that none of the participants had been infected by Omicron prior to BD8, 181 the anti-Omicron BA.1 neutralizing activity at this time point originated from cross-reactive 182 antibodies elicited by prior variant infections. Thus, the difference between anti-D614G and anti-183 BA.1 nAb titers at BD8 represents the quantity of anti-D614G nAbs that failed to recognize 184 mutated epitopes on Omicron BA.1, resulting in a lack of neutralizing function against Omicron BA.1. For the remainder of the manuscript, we will use ΔnAb^E to represent the quantity of 185 186 antibodies able to neutralize D614G but not Omicron BA.1 due to mutations in the Omicron 187 spike. Similarly to the Delta wave subgroup, a significant proportion of previously infected 188 individuals in the Omicron wave subgroup exhibited anti-D614G and anti-Omicron nAb titers 189 below the detection threshold at BD8 (Extended Data Table 1). The absence of detectable nAbs 190 was also more pronounced when the variant causing prior exposure and the spike used in the 191 neutralization assay were mismatched. (Extended Data Table 1). Roche Elecsys anti-192 nucleocapsid assay remained robust in detecting prior infection ³³, despite low nAb titer level 193 (Extended Data Table 1).

194 Fig. 2e shows the anti-D614G and the anti-BA.1 nAb titers at BD8 for participants included in 195 the Omicron wave analysis. The nAb GMT against D614G was 122 (95% CI 103 - 145) and 30 196 (95% CI 27 - 34) for antibodies that could neutralize BA.1, representing an average 4.01 (95% 197 CI (3.53 - 4.58) -fold reduction attributed to the immune evasive properties of Omicron. The 198 anti-D614G and anti-BA.1 nAb titers (in log scale) at BD 8 were modestly correlated (Pearson 199 correlation coefficient 0.64, p<0.0001). Comparing the nAb titers between individuals who were 200 infected during the Omicron wave vs. those who were not infected, we did not find significant differences in GMT levels for anti-D614G nAb, anti-BA.1 nAb, or ΔnAb^{E} (Fig. f-h). However, 201 202 it is worth noting that the point estimates of GMTs were higher for uninfected individuals 203 compared to infected individuals across all three measurements.

205 Pre-exposure nAb titer as CoP against variant infection

206 We conducted mediation analyses in a household transmission modelling framework to 207 investigate how nAb titers against SARS-CoV-2 variants at the onset of a SARS-CoV-2 wave 208 mediate the risk of infection during the corresponding epidemic wave. Specifically, following the causal inference framework proposed by Halloran, et al. ³⁴, we introduced SARS-CoV-2 209 210 transmission probabilities as causal parameters, representing either the risk of acquiring infection 211 from the general community or the per-contact transmission risk within the household. 212 Transmission probabilities were dependent on an individual's prior infection history, the level of 213 pre-existing nAb titers (mediators), and other confounding factors (age, gender, comorbidities). 214 We fitted a chain-binomial household transmission model, parametrized by the transmission 215 probabilities, to the infection outcomes of the Delta and Omicron waves among all subgroup 216 participants and evaluated how the level of nAb titers mediated SARS-CoV-2 transmission 217 probability. The details of the mediation analysis are described in the Methods Section 3.

218 For the Delta wave mediation analysis, we considered anti-D614G nAb titer at BD5 as 219 candidate mediator of protection and the quantity of antibodies that had waned from peak (ΔnAb^{W}) as putative negative control (i.e., we hypothesize that antibodies lost due to waning 220 221 could not conceivably contribute to protection). For the Omicron wave, we considered anti-BA.1 222 nAb titer at BD8 as candidate mediator of protection and the quantity of nAbs that escape 223 Omicron neutralization (ΔnAb^E) at BD8 as putative negative control. We used the term "direct 224 effect" from the causal inference framework to refer to the effect of exposure (prior infection) on 225 the outcome (repeat infection during the Delta or Omicron wave) absent the mediators (nAb 226 titers). Conversely, the term "indirect effect" represents the effect of exposure (prior infection) 227 on the outcome (repeat infection) that operates through the mediators (nAb titers). We estimated 228 both the direct effect of prior infection and effects mediated through specific nAb titers against 229 serologically confirmed SARS-CoV-2 infections. We report the estimates of the mediation 230 analysis for both Delta and Omicron wave in Table 2. For the ease of interpretation, we then 231 translate the estimated odds ratios into risk reductions (1 - odds ratio), along with other estimates 232 in causal diagrams depicted in Fig. 3.

Our findings indicate that immunity derived from prior infection, overall, reduced the risk of contracting a Delta wave infection by 61% (95%CI: 59% - 63%) (Fig 3a). Notably, nAbs

235 represented an important mediator of this overall protection: for every 10-fold increase in the 236 anti-D614G nAb titers at BD5, the risk of infection decreased by 40% (95% CI 19% - 56%). In 237 contrast, the decline in nAbs from peak levels to BD5 (ΔnAb^W) showed no contribution to the 238 overall protection, with a risk reduction per 10-fold increase of -1% (95%CI: -21% - 16%). This 239 result indicated that waning of neutralizing antibodies results in waning of protection, in 240 agreement with our hypothesis. Furthermore, we estimated that the protection mediated through 241 anti-D614G nAbs at BD5 accounted for 37% (95% CI: 34% - 40%) of the overall protection 242 derived from prior infection, suggesting that over half of the protection against Delta was not 243 mediated by serum nAbs against D614G. Lastly, our analysis indicated that individuals 244 reinfected with the Delta variant were 78% (95% CI: 24% - 94%) less likely to transmit the 245 infection to other household members compared to those who experienced primary infections 246 (Fig. 3a). This finding suggested that even in cases where prior immunity is not sufficient to 247 block reinfection with the Delta variant, infection-induced immunity still offered sizable 248 mitigation against onward transmission.

249 The causal diagram depicting the mediation analysis for the Omicron wave is illustrated in 250 Fig. 3b. Our findings indicate that, overall, prior infection-derived immunity resulted in a 37% 251 (95% CI: 35% – 38%) reduction in the risk of contracting an Omicron wave infection, a notably 252 lower effect compared to that of the Delta wave. We observed that, anti-Omicron nAbs at BD8 253 significantly mediated protection against the Omicron BA.1/2 variants: for every 10-fold 254 increase in anti-Omicron nAb titers, the risk of Omicron BA.1/2 infection decreased by 28% 255 (95% CI: 6% - 44%). Conversely, antibodies unable to neutralize Omicron due to immune 256 escape (ΔnAb^E) did not mediate protection against Omicron BA.1/2 infection, with risk 257 reduction of -1% (95% CI: -21% – 16%) per 10-fold titer increase. Furthermore, we estimated 258 that the protection mediated through anti-BA.1 nAbs at BD8 accounted for only 11% (95% CI: 259 9% - 12%) of the total protection conferred by prior exposure. This, coupled with the observation 260 that Omicron BA.1 caused an average of 4.01-fold drop in nAb titers (Fig. 2e), underscores 261 Omicron BA.1/2's ability to evade host protective immunity mediated through nAbs. 262 Additionally, in contrast to the Delta wave, individuals reinfected with the Omicron variant were 263 as likely to transmit the infection to other household members compared to those who 264 experienced primary infections (risk reduction: -17%, (95% CI: -110% - 35%)). These

265 observations suggested that Omicron not only evaded prior immunity's protection against266 acquisition of infection but also escaped protection against onward transmission.

267 Although neutralizing titers measured at BD5 and BD8 offered a temporally proximate 268 evaluation of protective immunity preceding the onset of the Delta and Omicron waves, we 269 could not identify the immune mediators responsible for the direct effects of prior immunity (i.e., 270 the fraction of protection that was not mediated by nAbs) due to lack of additional serum 271 biomarkers. We could however estimate the potential for these direct effects to wane over time. 272 To do so, we modeled an exponential decline for the direct effect based on the time elapsed since 273 prior infection and jointly estimated the duration of protection for both the Delta and Omicron 274 waves' analysis. We found that protection not mediated by nAbs decreased with time, with a 275 waning half-life of 121 (95% CI: 72 - 242) days (Fig. 3, Table 2). After adjusting for waning, the 276 effect sizes of protection from direct effects were similar for both variants, with odds ratios of 277 acquiring infection (compared to naïve individuals) of 0.34 (95% CI: 0.17, 0.68) and 0.29 (95% 278 CI: 0.17, 0.50) for the Delta and Omicron wave, respectively, in the absence of waning (Table 2). 279 These results suggested that, while Omicron escaped pre-existing neutralizing antibodies, 280 protection from other immune effectors was preserved against this variant. The waning half-life 281 of protection not mediated by nAbs was estimated at approximately 4 months in our study, 282 comparable to the reported waning timescale of T-cell immunity ^{35,36}. Several sensitivity 283 analyses demonstrating the robustness of the findings of the mediation analysis were reported in 284 the Methods Section 3.2 - 3.4.

285

286

287 Discussion

In this cohort of unvaccinated individuals, we found that nAb titers immediately before the onset of the Delta wave (i.e., anti-D614G nAb level at BD5) correlated with protection against Delta wave infections. Moreover, we demonstrated that nAb titers lost over time due to waning (i.e., ΔnAb^W) were not associated with protection, aligning with the expectation that waning of nAbs in serum corresponds to waning of clinical protection. For the Omicron wave subgroup, we further investigated the impact of immune escape against protection mediated through nAbs. We found that only anti-Omicron BA.1 nAbs correlated with protection against infection during the

295 Omicron BA.1/2 wave, whereas anti-D614G nAbs that were unable to neutralize Omicron BA.1 296 due to spike escape mutations did not protect. This indicated that antibodies capable of 297 neutralizing D614G but not Omicron BA.1 in vitro translates to a diminished protection against 298 Omicron BA.1/2 infection among PHIRST-C participants. The identification of variant-299 neutralizing antibodies derived from infection-induced immunity as CoPs against infections for 300 both Delta and Omicron variants aligns with findings from studies on variant-specific correlates for vaccine-induced or hybrid immunity ^{21–24}. Considering that antibody-mediated protection 301 302 against acquisition of infection likely operates at the mucosal site rather than in serum, it is interesting that serum antibodies levels can anticipate protection ²⁶. In a recent analysis of the 303 304 data from the COVE trial, Zhang et. al. further demonstrated that boosting of nAb titers against 305 Omicron by a third dose of mRNA-1273 vaccine, afforded additional protection against Omicron compared to individuals who only received 2 doses of the mRNA-1273 vaccine. ²² Collectively, 306 307 these empirical data lend support for using nAbs against circulating variant as immuno-bridging 308 markers for periodic vaccine updates.

309 While a comprehensive understanding of the role of nAbs in SARS-CoV-2 protection is 310 important, a key finding of our study is that nAb titers did not fully mediate protection conferred 311 by prior infection. In the case of the Delta wave subgroup, we estimate that anti-D614G nAbs mediate 37% of protection, a proportion comparable to vaccine-induced nAbs¹⁵. In contrast, for 312 313 the Omicron BA.1/2 wave subgroup, anti-Omicron BA.1 nAbs are estimated to mediate only 11% 314 of protection, which was substantially lower than that observed for the Delta wave. This low 315 percentage of protection mediated by nAbs for the Omicron BA.1/2 wave could be attributed to 316 the highly immune evasive nature of Omicron against neutralizing activity. Omicron effectively 317 rendered a significant proportion of serum anti-D614G nAbs nonfunctional against Omicron. 318 The large proportion of overall protection that was not mediated by nAbs could be explained by 319 a variety of immune mechanisms, including the Fc-effector function of binding antibodies, and T-cell functions, both of which are resilient against mutations in VOCs^{14,37}. Additionally, 320 321 SARS-CoV-2 initially infects and predominantly transmits through the upper respiratory tract. 322 Mucosal immunity in the upper respiratory tract therefore likely plays a key role in preventing SARS-CoV-2 infection, and may not be fully represented by immune markers in serum ³⁸. Our 323 324 study validates the use of serum nAbs as CoP against reinfection but also suggests potential important roles for other candidate functions that could act as "co-correlates" of protection ³⁹. 325

This is particularly important because these mechanisms may be more broadly cross-protective against future variants than neutralizing antibodies. Future CoP analyses incorporating measurements of T-cell immunity and non-neutralizing antibody functions, ideally at the mucosal site, could potentially disentangle these important protective mechanisms and inform design of next generation vaccines ^{26,40–42}.

331 Our study has several limitations. Firstly, the vaccination rate in the PHIRST-C cohort was 332 low at the time of the analysis; with <20% participants fully vaccinated prior to the Omicron 333 BA.1/2 wave (thus excluded from our analysis). Consequently, we lacked sufficient statistical 334 power to assess CoPs for vaccine-induced (or hybrid) immunity and compare with our findings 335 for infection-induced immunity in the same cohort. Secondly, we focused on SARS-CoV-2 336 infections that were ascertained by seroconversion or amnestic boosting of the anti-nucleocapsid 337 antibodies. However, not all PCR-positive SARS-CoV-2 infections led to systemic antibody 338 response ^{30,43,44}. Thus, our CoP analysis does not account for protection against abortive or 339 transient infections that do not lead to systemic antibody responses. We also could not evaluate 340 CoPs against symptomatic cases, as there was no systemic monitoring of SARS-CoV-2 341 symptoms for the cohort population during the Omicron BA.1/2 wave. Further, severe outcomes 342 (hospitalizations and deaths) due to SARS-CoV-2 infections were rare throughout the course of 343 the PHIRST-C study and evaluation of protection against those outcomes is under-powered. 344 Understanding protection against severe outcomes is important from both clinical and public 345 health prospective, thus warranting further studies. Thirdly, the strains of antigens used in 346 neutralization assay were not perfectly matched to the circulating variants in the CoP analysis. 347 For the Delta wave analysis, we evaluated anti-D614G antibody titers (rather than anti-Delta 348 titers). Although Delta is not as immune evasive as Omicron with respect to D614G, there are 349 substitutions on the spike of Delta (i.e., L452R, T478K) that are linked to moderate antigenic escape ^{45,46}. In addition, though infections were predominantly caused by the Delta variant 350 351 during the Delta wave epidemic, other variants also circulated at low levels during the same time period, including Alpha and C.1.2³⁰. Similarly, genomic surveillance revealed that while 352 353 Omicron BA.1 accounted for the majority of infections during the Omicron wave, Omicron BA.2 also co-circulated, with potential antigenic spike substitutions (e.g., T376A, D405N, R408S) that 354 were not present in BA.1^{30,46,47}. Thus, using a BA.1-specific neutralizing assay may introduce 355 356 bias in our CoP analysis, particularly against Omicron BA.2. Lastly, we only measured serum

antibodies, but did not have any information on antibody response at the mucosal site or on cellmediated immunity. While serum IgG nAbs may transudate into the nasal mucosa and thereby
play a role in protection, the contribution of locally produced nasal IgA nAb remains to be
investigated.

Moving forward, future works focusing on understanding how protective immunity accumulates through repeated infections, vaccinations, and hybrid immunity, and identifying a suite of predictive markers of protection reflecting different arms of immune responses, are key to anticipating long-term SARS-CoV-2 burden, optimizing vaccine boosters, and designing next generation SARS-CoV-2 vaccines.

366

367 Acknowledgment

368 The findings and conclusions in this report are those of the authors and do not necessarily 369 represent the official position of the NIH or the U.S. Centers for Disease Control and Prevention. 370 **Funding:** This work was supported by the National Institute for Communicable Diseases of the 371 National Health Laboratory Service and the U.S. Centers for Disease Control and Prevention 372 [cooperative agreement number: 6 U01IP001048] and Wellcome Trust (grant number 373 221003/Z/20/Z) in collaboration with the Foreign, Commonwealth and Development Office, 374 United Kingdom. PLM and JNB are supported by the Bill and Melinda Gates Foundation 375 through the Global Immunology and Immune Sequencing for Epidemic Response (GIISER) 376 program (INV-030570) and receive funding from the Wellcome Trust (226137/Z/22/Z). PLM is 377 supported by the South African Research Chairs Initiative of the Department of Science and 378 Innovation and National Research Foundation of South Africa and the SA Medical Research 379 Council SHIP program.

380 Author Contributions Statement

KS, JNB, ST, JK, AvG, MLM, NW, JM, NAM, KK, LL, CV, PLM, CC designed the experiments.
JNB, CC, JK, PLM and ST accessed and verified the underlying data. JNB, ST, JK, VSM, QM,

383 HK, AvG, MLM, NW, JM, MC, NAM, KK, LL, JdT, TM, PLM, CC collected the data and

384 performed laboratory experiments. KS, JNB, ST, JK, AvG, MLM, NW, JM, MC, NAM, KK, LL,

JdT, TM, CV, and CC analyzed the data and interpreted the results. KS, JNB, CV, PLM, and CC
drafted the manuscript. All authors critically reviewed the article. All authors had access to all
the data reported in the study.

388 **Competing Interests Statement**

389 CC has received grant support from Sanofi Pasteur, US CDC, the Bill & Melinda Gates 390 Foundation, the Taskforce for Global Health, Wellcome Trust and the South African Medical 391 Research Council. AvG has received grant support from Sanofi Pasteur, Pfizer related to 392 pneumococcal vaccine, CDC and the Bill & Melinda Gates Foundation. NW reports grants from 393 Sanofi Pasteur and the Bill & Melinda Gates Foundation. NAM has received a grant to his 394 institution from Pfizer to conduct research in patients with pneumonia and from Roche to collect 395 specimens to assess a novel TB assay. JM has received grant support from Sanofi Pasteur. The 396 remaining authors declare no competing interests

397 Consortia Authorship

The PHIRST-C group: Jinal N. Bhiman^{2,3}, Amelia Buys⁴, Maimuna Carrim^{4,7}, Cheryl Cohen^{4,5},
Linda de Gouveia⁴, Mignon du Plessis^{4,7}, Jacques du Toit¹¹, Francesc Xavier Gómez-Olivé¹¹,
Kathleen Kahn¹¹, Kgaugelo Patricia Kgasago⁹, Jackie Kleynhans^{4,5}, Retshidisitswe Kotane⁴,
Limakatso Lebina⁹, Neil A Martinson^{9,10}, Meredith L McMorrow^{6,8}, Tumelo Moloantoa⁴, Jocelyn
Moyes^{4,5}, Stefano Tempia^{4,5,6}, Stephen Tollman¹¹, Anne von Gottberg^{4,7}, Floidy Wafawanaka¹¹,
Nicole Wolter^{4,7}

405 **Tables:**

406 **Table 1: Characteristics of the PHIRST-C cohort's Delta wave subgroup and Omicron wave subgroup** 407 **populations, respectively.** *PLWH: people living with HIV. **Here it indicates if a participant of the Delta/Omicron

408 wave subgroup was infected (either primary or repeat infection) during the Delta/Omicron BA.1 wave.

	Delta wave subgroup	Omicron wave subgroup
	196 households	184 households
Characteristics	Number of individuals (%)	Number of individuals (%)
All	797 (100)	535 (100)
Study site		
Rural	427 (54)	300 (56)
Urban	370 (46)	235 (44)
Age group, in years		
0-4	90 (11)	77 (14)
5-12	270 (34)	231 (43)
13-18	111 (14)	80 (15)
19-34	126 (16)	84 (16)
35-59	126 (16)	43 (8)
60+	74 (9)	20 (4)
Sex		
Male	324 (41)	229 (43)
Female	473 (59)	306 (57)
Household size		
3-5	372 (47)	254 (48)
6-8	264 (33)	197 (37)
9-12	124 (15)	72 (13)
13+	37 (5)	12 (2)
HIV status		
Negative	673 (85)	496 (93)
PLWH [*]	97 (12)	31 (6)
Unknown	27 (3)	8 (1)
Prior immunity		
Naive	544 (68)	193 (36)
Previously infected	253 (32)	342 (64)
Variant of prior infection:		
D614G	113 (14)	61 (11)
Beta	140 (18)	120 (22)
Delta	_	161 (31)
Infected ^{**}		
Yes	273 (34)	359 (67)
No	524 (66)	176 (33)

- 409 Table 2: Mediation analysis for nAbs as CoPs against Delta and Omicron wave infections, with a waning
- 410 model for direct effect. Average and 95% CIs are provided for each of the model parameters. ΔnAb^{W} : the quantity
- 411 of anti-D614G nAbs waned from peak level to that at BD5. ΔnAb^{E} : the quantity of antibodies that can neutralize
- 412 D614G but fail to neutralize Omicron BA.1 at BD8 due to Omicron's immune escape.

Wave		Delta	Omicron	
Protection against reinfection	Direct effect (Protection absent of nAbs)	Effect size (odds ratio, absent of waning)	0.34 (0.17, 0.68)	0.29 (0.17, 0.50)
		Waning half-life (days)	121 (72, 242)	
	Mediators effect (Protection from nAbs)	Anti-D614G nAb (odds ratio, per 10-fold increase)	0.60 (0.44, 0.81)	_
		ΔnAb^{W} (odds ratio, per 10-fold increase)	1.01 (0.74, 1.37)	_
		Anti-Omicron BA.1 nAb (odds ratio, per 10-fold increase)	_	0.72 (0.56, 0.94)
		ΔnAb^E (odds ratio, per 10-fold increase)	_	1.01 (0.84, 1.21)
	(relati	Total protection ve risk compared to naïve individuals)	0.39 (0.37, 0.41)	0.63 (0.62, 0.65)
	Proportion of protection mediated by nAbs		37% (34%, 40%)	11% (9%, 12%)
Protection against onward transmission (Odds ratio compared to naïve individuals)		0.22 (0.06, 0.76)	1.17 (0.65, 2.10)	

413

415 **Figures:**





417 Fig. 1: Timing of cohort sample collections with respect to SARS-CoV-2 variants' circulations in the two study 418 sites. a, Timing of the blood draws with respect to the SARS-CoV-2 epidemic waves in the rural site (Agincourt) of 419 the PHIRST-C cohort. Bar plot represents the weekly incidence (per 100,000 population) of SARS-CoV-2 cases 420 from routine surveillance data collected in Ehlanzeni District, Mpumalanga Province (where rural participants 421 reside). The shaded areas represent the timing of the serum sample collections for the 10 blood draws. Each curve 422 within the shaded area indicates the cumulative proportion of participants' serum samples collected over time. The 423 Delta wave subgroup analysis focuses on nAb titers among serum samples collected during blood draw 5 (blue 424 shade); the Omicron BA.1 wave analysis focuses on nAb titers among serum samples collected during blood draw 8 425 (red shade). b, Same as (A), but for the urban site (Klerksdorp). The routine surveillance data (bar plot) were 426 collected from Dr. Kenneth Kaunda District, North West Province (where urban participants reside).



428





448 Figure 3: Causal diagrams for the mediation analyses. a: Causal diagram of the Delta wave mediation analysis 449 showing the hypothesized relationship between prior immunity (induced by prior SARS-CoV-2 infection) and 450 SARS-CoV-2 infection (outcome of interest) during Delta wave. The mediators of interest are anit-D614G nAbs at 451 BD5 and ΔnAb^{W} (the quantity of anti-D614G nAbs waned from peak level to that at BD5). The direct effect 452 represents protection operating through immune mechanisms other than the mediators of interest. We hypothesize 453 that the direct effect could wane over time since the initial immune exposure. For the prospective cohort data, both 454 mediator-outcome confounding and exposure-outcome confounding factors need to be adjusted for in the mediation 455 analysis, as the immune exposure (prior SARS-CoV-2 infection) was not randomly assigned (unlike SARS-CoV-2 456 randomized-control vaccine trials where vaccination was randomly assigned to the participants). Furthermore, 457 cohort participants may experience heterogenous levels of SARS-CoV-2 exposure due to different intensity SARS-458 CoV-2 transmission in their household settings. We adjust this by embedding the mediation analysis in a mechanistic 459 household transmission model (detailed in Methods Section 3). We also look at the impact of prior immunity on the 460 reduction of onward transmission, conditional on the failure of preventing reinfection. The estimates of the Delta 461 wave mediation analysis are presented in Table 2. b: Same as a but for the Omicron wave analysis. The mediators of 462 interest are anit-BA.1 nAbs at BD8 and ΔnAb^E (the quantity of antibodies that can neutralize D614G but fail to 463 neutralize Omicron BA.1 at BD8 due to Omicron's immune escape.). The estimates of the Omicron wave mediation 464 analysis are presented in Table 2.

465

467 **Reference:**

- 468 1. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the
- 469 COVID-19 pandemic. https://www.who.int/news/item/05-05-2023-statement-on-the-
- 470 fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-
- 471 regarding-the-coronavirus-disease-(covid-19)-pandemic.
- 472 2. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/.
- 473 3. WHO COVID19 Vaccine Tracker. https://covid19.trackvaccines.org/agency/who/.
- 474 4. Watson, O. J. *et al.* Global impact of the first year of COVID-19 vaccination: a
- 475 mathematical modelling study. *Lancet Infect. Dis.* 22, 1293–1302 (2022).
- 476 5. Gozzi, N. *et al.* Estimating the impact of COVID-19 vaccine inequities: a modeling study.
- 477 *Nat. Commun.* **14**, 3272 (2023).
- 478 6. Wang, Q. et al. Mapping global acceptance and uptake of COVID-19 vaccination: A

479 systematic review and meta-analysis. *Commun. Med.* **2**, 113 (2022).

- 480 7. Lazarus, J. V. *et al.* A survey of COVID-19 vaccine acceptance across 23 countries in 2022.
- 481 *Nat. Med.* **29**, 366–375 (2023).
- 482 8. Bergeri, I. *et al.* Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A

483 systematic review and meta-analysis of standardized population-based studies. *PLoS Med.*

- **484 19**, e1004107 (2022).
- 485 9. Lewis, H. C. *et al.* SARS-CoV-2 infection in Africa: a systematic review and meta-analysis
- 486 of standardised seroprevalence studies, from January 2020 to December 2021. *BMJ Glob*487 *Health* 7, (2022).
- 488 10. Wang, Q. *et al.* Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4
 489 and BA.5. *Nature* 608, 603–608 (2022).

- 490 11. Ito, J. et al. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the
- 491 emergence of BQ.1.1 variant. *Nat. Commun.* **14**, 2671 (2023).
- 492 12. Cao, Y. *et al.* BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
- 493 *Nature* **608**, 593–602 (2022).
- 494 13. Cao, Y. *et al.* Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD
- 495 evolution. *Nature* **614**, 521–529 (2023).
- 496 14. Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-
- 497 CoV-2 infection and COVID-19 disease. *Immunol. Rev.* **310**, 6–26 (2022).
- 498 15. Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine
- 499 efficacy clinical trial. *Science* **375**, 43–50 (2022).
- 500 16. Fong, Y. *et al.* Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy
 501 clinical trial. *Nat. Commun.* 14, 331 (2023).
- 502 17. Fong, Y. *et al.* Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose
 503 vaccine efficacy clinical trial. *Nat Microbiol* 7, 1996–2010 (2022).
- 18. Feng, S. *et al.* Correlates of protection against symptomatic and asymptomatic SARS-CoV-
- 505 2 infection. *Nat. Med.* 27, 2032–2040 (2021).
- 506 19. Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection
 507 from symptomatic SARS-CoV-2 infection. *Nat. Med.* 27, 1205–1211 (2021).
- 508 20. Earle, K. A. *et al.* Evidence for antibody as a protective correlate for COVID-19 vaccines.
 509 *Vaccine* 39, 4423–4428 (2021).
- 510 21. Atti, A. et al. Antibody correlates of protection against Delta infection after vaccination: A
- 511 nested case-control within the UK-based SIREN study. J. Infect. 87, 420–427 (2023).

- 512 22. Zhang, B. et al. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-
- 513 1273 in the COVE trial. *bioRxiv* (2023) doi:10.1101/2023.10.15.23295628.
- 514 23. Hertz, T. et al. Correlates of protection for booster doses of the SARS-CoV-2 vaccine
- 515 BNT162b2. Nat. Commun. 14, 4575 (2023).
- 516 24. Gilboa, M. et al. Factors Associated With Protection From SARS-CoV-2 Omicron Variant
- 517 Infection and Disease Among Vaccinated Health Care Workers in Israel. JAMA Netw Open 518
- **6**, e2314757 (2023).
- 519 25. Tang, J. et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination.
- 520 Sci Immunol 7, eadd4853 (2022).
- 521 26. Knisely, J. M. et al. Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities-522 workshop report. NPJ Vaccines 8, 53 (2023).
- 523 27. Miyamoto, S. et al. Infectious virus shedding duration reflects secretory IgA antibody
- 524 response latency after SARS-CoV-2 infection. Proc. Natl. Acad. Sci. U. S. A. 120,
- 525 e2314808120 (2023).
- 526 28. Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361-379 (2023).
- 527 29. Cohen, C. et al. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an
- 528 urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21. Lancet Infect.
- 529 Dis. (2022) doi:10.1016/S1473-3099(22)00069-X.
- 530 30. Sun, K. et al. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the 531 Omicron era in South Africa. Nat. Commun. 14, 246 (2023).
- 532 31. Pulliam, J. R. C. et al. Increased risk of SARS-CoV-2 reinfection associated with emergence
- 533 of Omicron in South Africa. Science eabn4947 (2022).

- 534 32. Sun, K. et al. SARS-CoV-2 transmission, persistence of immunity, and estimates of
- 535 Omicron's impact in South African population cohorts. *Sci. Transl. Med.* eabo7081 (2022).
- 536 33. Elecsys® Anti-SARS-CoV-2. Diagnostics
- 537 https://diagnostics.roche.com/us/en/products/params/elecsys-anti-sars-cov-2.html.
- 538 34. Halloran, M. E. & Struchiner, C. J. Causal inference in infectious diseases. *Epidemiology* 6,
- **539** 142–151 (1995).
- 540 35. Cohen, K. W. *et al.* Longitudinal analysis shows durable and broad immune memory after
- 541 SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. *Cell*
- 542 *Rep Med* 2, 100354 (2021).
- 543 36. Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months after
 544 infection. *Science* 371, (2021).
- 545 37. Eser, T. M. et al. Nucleocapsid-specific T cell responses associate with control of SARS-
- 546 CoV-2 in the upper airways before seroconversion. *Nat. Commun.* **14**, 2952 (2023).
- 547 38. Havervall, S. *et al.* Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron
- 548 Infection. N. Engl. J. Med. 387, 1333–1336 (2022).
- 549 39. Plotkin, S. A. Vaccines: correlates of vaccine-induced immunity. *Clin. Infect. Dis.* 47, 401–
 550 409 (2008).
- 40. Morens, D. M., Taubenberger, J. K. & Fauci, A. S. Rethinking next-generation vaccines for
 coronaviruses, influenzaviruses, and other respiratory viruses. *Cell Host Microbe* 31, 146–
- **553** 157 (2023).
- 554 41. Topol, E. J. & Iwasaki, A. Operation Nasal Vaccine-Lightning speed to counter COVID-19.
 555 *Science immunology* vol. 7 eadd9947 (2022).

- 42. Fact Sheet: HHS Details \$5 Billion 'Project NextGen' Initiative to Stay Ahead of COVID-
- 557 19. https://aspr.hhs.gov/newsroom/Pages/ProjectNextGen-May2023.aspx.
- 558 43. Liu, W. et al. Predictors of Nonseroconversion after SARS-CoV-2 Infection. Emerg. Infect.
- 559 *Dis.* 27, 2454–2458 (2021).
- 560 44. Lindeboom, R. G. H. et al. Human SARS-CoV-2 challenge resolves local and systemic
- 561 response dynamics. *medRxiv* (2023) doi:10.1101/2023.04.13.23288227.
- 562 45. McCallum, M. et al. Molecular basis of immune evasion by the Delta and Kappa SARS-
- 563 CoV-2 variants. *Science* **374**, 1621–1626 (2021).
- 564 46. Wilks, S. H. *et al.* Mapping SARS-CoV-2 antigenic relationships and serological responses.
- *Science* **382**, eadj0070 (2023).
- 566 47. Tegally, H. *et al.* Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South
 567 Africa. *Nat. Med.* (2022) doi:10.1038/s41591-022-01911-2.
- 48. Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African
- 569 COVID-19 donor plasma. *Nat. Med.* (2021) doi:10.1038/s41591-021-01285-x.
- 49. Netzl, A. *et al.* Analysis of SARS-CoV-2 Omicron Neutralization Data up to 2022-01-28.
- *bioRxiv* 2021.12.31.474032 (2023) doi:10.1101/2021.12.31.474032.
- 572
- 573

574 Methods

575 **Ethics statement:** The PHIRST-C protocol was approved by the University of Witwatersrand 576 Human Research Ethics Committee (Reference 150808) and the U.S. Centers for Disease 577 Control and Prevention's Institutional Review Board relied on the local review (#6840). The 578 protocol was registered on clinicaltrials.gov on 6 August 2015 and updated on 30 December 579 2020 (https://clinicaltrials.gov/ct2/show/NCT02519803). Participants receive grocery store 580 vouchers of ZAR50 (USD 3) per visit to compensate for time required for specimen collection 581 and interview. All participants provided informed consent for study participation. For minors, 582 consent was obtained from the parent or guardian.

583 1. Inferring Delta and Omicron wave infections based on longitudinal serum samples.

584 We have previously described the serologic inference method for SARS-CoV-2 infections among the PHIRST-C cohort participants during the Delta wave (3rd SARS-CoV-2 wave) and the 585 Omicron wave (4th SARS-CoV-2 wave) ³⁰. To briefly summarize, ascertainment of Delta wave 586 587 infections was based on the serial serologic readout of blood draws 5 and 6 (both before the 588 Delta wave, figure 1A-B), and 8 (post Delta wave), measured by the Roche Elecsys Anti-SARS-CoV-2 nucleocapsid assay ³³. The participants' serologic trajectories were then grouped into 13 589 590 categories of distinct serum antibody patterns, reflecting the rise, waning, and/or amnestic 591 boosting of anti-nucleocapsid antibody levels. Because the Delta wave was also covered by 592 intense virologic sampling with twice-weekly nasopharyngeal swab collection, we grouped the 593 13 serologic categories into indicators of either presence or absence of SARS-CoV-2 infection to 594 achieve the highest concordance with rRT-PCR-confirmed Delta infections. The Omicron wave 595 was not covered by the intense PCR testing; however, the timing of blood draws 8, 9, and 10 596 with respect to the Omicron wave is similar to that of blood draws 5, 6, and 8 with respect to the 597 Delta wave (figure 1A-B). We thus apply the same classification method of serial serologic 598 trajectories defined by blood draws 8, 9, and 10 to infer SARS-CoV-2 infections during the 599 Omicron BA.1/2 wave.

600 2. Laboratory methods

601 2.1 Serum nAb titers against SARS-CoV-2 D614G and BA.1 variants (Lentiviral
602 Pseudovirus Production and Neutralization Assay)

Virus production and pseudovirus neutralization assays were done as previously described ⁴⁸. 603 604 Briefly, 293T/ACE2.MF cells modified to overexpress human ACE2 (kindly provided by M. 605 Farzan (Scripps Research)) were cultured in DMEM (Gibco BRL Life Technologies) containing 10% heat-inactivated serum (FBS) and 3 µg ml⁻¹ puromycin at 37 °C, 5% CO₂. Cell monolayers 606 607 were disrupted at confluency by treatment with 0.25% trypsin in 1 mM EDTA (Gibco BRL Life 608 Technologies). The SARS-CoV-2, Wuhan-1 spike, cloned into pCDNA3.1 was mutated using the 609 QuikChange Lightning Site-Directed Mutagenesis kit (Agilent Technologies) and NEBuilder 610 HiFi DNA Assembly Master Mix (NEB) to include D614G (wild-type) or lineage defining 611 mutations for Delta (T19R, 156-157del, R158G, L452R, T478K, D614G, P681R and D950N) 612 and), Omicron BA.1 (A67V, 69-70del, T95I, G142D, 143-145del, 211del, L212I, 214EPE, 613 G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, 614 Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, 615 Q954H, N969K, L981F), Omicron BA.2 (T19I, L24S, 25-27del, G142D, V213G, G339D, S371F, 616 S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, 617 Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K). 618 Pseudoviruses were produced by co-transfection in 293T/17 cells with a lentiviral backbone 619 (HIV-1 pNL4.luc encoding the firefly luciferase gene) and either of the full-length SARS-CoV-2 620 spike plasmids with PEIMAX (Polysciences). Culture supernatants were clarified of cells by a 621 0.45μ M filter and stored at -70 °C. Plasma samples were heat-inactivated and clarified by 622 centrifugation. Pseudovirus and serially diluted plasma/sera were incubated for 1 h at 37 °C, 5% CO₂. Cells were added at 1×10^4 cells per well after 72 h of incubation at 37 °C, 5% CO₂, 623 624 luminescence was measured using PerkinElmer Life Sciences Model Victor X luminometer. 625 Neutralization was measured as described by a reduction in luciferase gene expression after 626 single-round infection of 293T/ACE2.MF cells with spike-pseudotyped viruses. Titers were 627 calculated as the reciprocal plasma dilution (ID_{50}) causing 50% reduction of relative light units.

Noting that we measured neutralization titer using a lentiviral-backboned pseudovirus neutralization assay. A systematic review of Omicron neutralization data showed that pseudovirus neutralization assays tend to report higher neutralizing titers compared to live-virus assays. The titer drops from wild type to Omicron also tend to be less pronounced for pseudovirus platforms, suggesting the pseudovirus assay may underestimate Omicron's capability to escape neutralization ⁴⁹.

634

635 2.2 SARS-CoV-2 spike enzyme-linked immunosorbent assay (ELISA)

636 For ELISA, Hexapro SARS-CoV-2 full spike protein with the D614G substitution was expressed 637 in Human Embryonic Kidney (HEK) 293F suspension cells by transfecting the cells with the 638 respective expression plasmid. After incubating for 6 days at 37°C, proteins were first purified 639 using a nickel resin followed by size exclusion chromatography. Relevant fractions were 640 collected and frozen at -80°C until use. Two µg/mL of D614G spike protein was used to coat 96-641 well, high-binding plates (Corning) and incubated overnight at 4°C. The plates were incubated in 642 a blocking buffer consisting of 1x PBS, 5% skimmed milk powder, 0.05% Tween 20. Plasma 643 samples were diluted to 1:100 starting dilution in a blocking buffer and added to the plates. IgG 644 secondary antibody (Merck) was diluted to 1:3000 in blocking buffer and added to the plates 645 followed by TMB substrate (Thermofisher Scientific). Upon stopping the reaction with 1 M 646 H2SO4, optical density (OD) was measured at 450 nm. The monoclonal antibodies (mAbs) 647 CR3022 and Palivizumab were used as the positive and negative controls respectively.

648

649 3. Mediation analyses and household transmission model fitted to observed infections in the650 cohort.

651 Here we blend concepts from causal inference and infectious disease transmission models. The 652 stability assumption in causal inference stipulates that the outcome of an individual does not 653 depend on the outcome of others, which is often violated in infectious disease dynamics. This is 654 because the spread of infectious diseases requires pathogens to be transmitted from one host to 655 another. In other words, the infection outcome of one individual inherently depends on the infection outcome of others, and this is particularly pronounced in a household setting ³⁴. The 656 657 "dependent happening" nature of infectious disease dynamics violates the stability assumption. 658 As a result, the traditional regression approach for causal inference analysis cannot be applied to 659 infectious disease outcomes among individuals who can in theory transmit the disease from one to another. To overcome this, Halloran, et al. ³⁴ introduced the probability of infection 660 661 conditional on exposure to already infected individuals (transmission probability), as the causal 662 parameter. Using this proposed framework, we can investigate how the presence/absence of pre-

existing immunity along with the immunologic marker of interest could modulate probability of infection, after adjusting for levels of exposure to the infectious source(s). The corresponding causal inference framework requires modelling the transmission process explicitly. Under this framework, we conduct mediation analyses to investigate how nAb titers against variants at the start of a SARS-CoV-2 wave correlate with SARS-CoV-2 transmission risk, using the Delta and Omicron BA.1/2 waves as examples. We focus on the Delta and Omicron subgroup participants who have had a single or no prior infection. Specifically, we introduce the causal parameters:

670 671 • p_{ij}^k : the per-contact SARS-CoV-2 household transmission probability from infected individual *i* to individual *j* in household *k*.

672 673 • q_j^k : the overall probability of acquiring SARS-CoV-2 infection from outside the household by individual *j* of household *k* (probability of infection from the community).

674 We use e_i to indicate individual j's prior SARS-CoV-2 infection history, with $e_i = 0$ representing no prior infection reported before the start of Delta/Omicron BA.1/2 and $e_i = 1$ representing one 675 676 prior infection by the start of Delta/Omicron BA.1/2 wave. A prior SARS-CoV-2 infection $(e_i = 1)$ would induce immunologic responses, measured by a set of immune markers (i.e., 677 candidate mediators) $\{m_i | e_i = 1\}$ (e.g., nAb titers level). Then the household transmission 678 probability $p_{ij}^k = p_{ij}^k (e_j, \{m_j | e_j = 1\}, \{c_i, c_j, c_k\})$ can be expressed as a function of prior infection 679 status e_j , immunologic mediators of SARS-CoV-2 transmission probability $\{m_j | e_j = 1\}$ and 680 additional adjustment terms $\{c_i, c_j, c_k\}$, representing a set of potential confounding factors of 681 682 individual i, individual j, and household k (eg, age of the donor and/or recipient, comorbidities, household size, etc). Similarly, the community infection probability $q_i^k = q_i^k (e_i, \{m_i | e_i = i\})$ 683 1}, $\{c_i\}$) can be expressed as a function of individual *j*'s prior exposure history e_j , 684 immunological markers $\{m_i | e_i = 1\}$, and additional adjustment terms $\{c_i\}$, representing a set of 685 686 potential confounding factors of individual *j* (e.g., age or comorbidities).

687 The causal diagram of the mediation analysis framework is shown in Fig. 3. We fit a 688 household transmission model to the imputed household transmission chains based on an 689 Expectation-maximization (EM) algorithm (detailed in Section 4). Specifically, for the 690 Delta/Omicron BA.1/2 wave, if we look into a specific household k of size N, there are a total of

691 *n* individuals infected belonging to *L* distinct chains of transmission due to *L* independent 692 introductions of SARS-CoV-2 into the household. The uninfected individuals are N - n. We 693 denote P_j^k the likelihood of any individual *j* of household *k* having the observed infection status 694 over the Delta/Omicron BA.1/2 wave (i.e., either infected or not) in a particular realization of the 695 model. There are a few scenarios to write down P_j^k :

- Within a given transmission chain *l* ∈ *L*, the initial generation g^l_j = 0 always has an individual *j* acquiring infection from the general community (outside the household *k*).
 Thus, the probability of individual *j* being infected is P^k_j = q^k_j if *j* is the first individual to be infected in the chain.
- For infected individual *j* in the first generation of transmission chain *l*, i.e., $g_j^l = 1$, this individual would have to escape infection risk from the general community but get infected by the infected household member of $g_i^l = 0$. Thus, the probability of individual *j* being infected can be written as $P_j^k = (1 - q_j^k)p_{ij}^k$.
- For infected individual *j* in transmission chain *l* with generation greater than 1, i.e., $g_l > 1$, this individual has escaped infection risk from the general community as well as infected individuals *i* two generations away $(g_i^l \le g_j^l - 2)$ but got infected by an infector *i'* of *j*'s previous generation on the same transmission chain *l*. Thus, the probability of individual *j* being infected can be written as $P_j^k = (1 - q_j^k) \times \prod_{i \in \{g_i^l \le g_j^l - 2\}} (1 - p_{ij}^k) \times$

709
$$p_{i'j}^k$$
.

For uninfected individual *j* within household *k*, this individual has escaped infection risk
 from the general community as well as all the *n* infected individuals within the same
 household. Thus, the probability of individual *j* remaining uninfected can be written as
 *P*_j^k = (1 - q_j^k) × ∏_{i∈{n}}(1 - p_{ij}^k).

Then, within household *k* of size *N*, we can express the likelihood of transmission chain *l* as $\prod_{j\in l} P_j^k$; the likelihood of observing all infections within *k* can be expressed as $\prod_{l\in L} \prod_{j\in l} P_j^k$; the likelihood of observing *N* – *n* uninfected individuals can be expressed as $\prod_{j\in N-n} P_j^k$. Putting these together, the likelihood of observing one realization of the imputed (details of the EM

718 imputation method described in Section 4) households' transmission trees for Delta/Omicron719 wave can be expressed as:

$$L^{Delta/Omicron} = \prod_{k} L_{k}^{Delta/Omicron} \#(1)$$

720 Where the likelihood of a given household transmission chains configuration $L_k^{Delta/Omicron}$ can 721 be expressed as:

$$L_k^{Delta/Omicron} = \prod_{l \in L} \prod_{j \in l} P_j^k \left(p_{ij}^k, q_j^k \right) \times \prod_{j \in N-n} P_j^k \left(p_{ij}^k, q_j^k \right) \#(2)$$

722 In the remainder of the section, we will consider a few versions of the transmission model with 723 slightly different implementations for p_{ij}^k and q_j^k .

3.1 Model 1: waning model for prior exposure with serologically ascertained Delta andOmicron wave infections.

This is the transmission model presented in the main analysis of the manuscript (results of the model shown in Table 2. In this model, we consider that protection from prior infection unexplained by nAb titers wanes over time but is not dependent on the variant responsible for prior infection (i.e. prior D614G or Beta infections for the Delta wave analysis, and prior D614G, Beta, or Delta infections for the Omicron wave analysis). Additionally, in this model, both the Delta and Omicron wave infections were ascertained by serology based on approach describe in Methods Section 1.

733 More specifically, for the Delta wave, p_{ij}^k and q_j^k can be expressed as:

$$p_{ij}^{k} = \operatorname{expit} \begin{pmatrix} \epsilon \left(\frac{1}{2}\right)^{\frac{\Delta t}{\tau}} e_{j} + \left(\delta_{nAb}^{D614G} m_{j}^{D614G} + o_{\Delta nAb}^{waning} m_{j}^{waning}\right)^{e_{j}} + \lambda e_{i} + \\ \sum_{c_{i} \in \{c_{i}\}} \gamma_{c_{i}}c_{i} + \sum_{c_{j} \in \{c_{j}\}} \gamma_{c_{j}}c_{j} + \sum_{c_{k} \in \{c_{k}\}} \gamma_{c_{k}}c_{k} + \alpha_{s} \end{pmatrix} \#(3)$$

$$q_{j}^{k} = \operatorname{expit} \begin{pmatrix} \epsilon \left(\frac{1}{2}\right)^{\frac{\Delta t}{\tau}} e_{j} + \left(\delta_{nAb}^{D614G} m_{j}^{D614G} + o_{\Delta nAb}^{waning} m_{j}^{waning}\right)^{e_{j}} + \\ \sum_{c_{j} \in \{c_{j}\}} \gamma_{c_{j}}c_{j} + \sum_{c_{k} \in \{c_{k}\}} \gamma_{c_{k}}c_{k} + \beta_{s} \end{pmatrix} \#(4)$$

As described before, e_i indicates individual j's prior SARS-CoV-2 infection history, with $e_i = 0$ 734 representing uninfected individuals at the start of the Delta wave, $e_i = 1$ representing one prior 735 736 infection, and ϵ representing the effect size of the immune protection by prior infection not 737 mediated through anti-D614G nAbs (direct effect, Table 2). Δt is the elapsed time between prior 738 infection and blood draw 5 (the blood draw taken prior to the Delta wave which we use in this model) and τ is the waning half-life of ϵ (direct effect, Table 2). m_j^{D614G} represents the anti-739 D614G nAb titer at blood draw 5 and δ_{nAb}^{D614G} represents the effect size of m_j^{D614G} in mediating 740 infection probability p_{ij}^k against the Delta wave infection (mediator effect, Table 2) at blood draw 741 5. While m_i^{waning} represents the quantity of anti-D614G nAbs waned from peak level (measured 742 743 as the highest anti-D614G nAb titer level among the first 5 blood draws) to that at BD5 and $o_{\Delta nAb}^{waning}$ represents the effect size of m_i^{waning} in mediating transmission probability p_{ji}^k against 744 745 the Delta wave infection (mediator effect, Table 2) at blood draw 5. Note that the term $\delta_{nAb}^{D614G} m_j^{D614G} + o_{\Delta nAb}^{waning} m_j^{waning}$ only exists when $e_j = 1$. 746

We further evaluate whether breakthrough infections have reduced infectiousness compared to primary infections and may in turn affect p_{ij}^k . We use e_i to indicate individual *i*'s (the donor) prior SARS-CoV-2 infection history ($e_i = 0$ means no infection, and $e_i = 1$ represents one prior infection at the start of Delta wave). Further, λ represents the effect size of prior infection (in *i*) in reducing the infectiousness of reinfections.

We also consider confounding factors for donor *i* and recipient *j*, where c_i and γ_{c_i} represent infector *i*'s confounding factor (*i*'s age, sex) and effect size, respectively; c_j and γ_{c_j} represent *j*'s confounding factor (*j*'s age/sex-specific susceptibility (biology), age/sex- and site-specific susceptibility (behavioral), HIV infection status) and effect size, respectively; c_k and γ_{c_k} represent household *k*'s confounding factor (household size) and effect size, respectively. Lastly, α_s and β_s are logits of the baseline risks for household and community exposures. All parameters' effect sizes are measured in the log of odds ratios.

759 Similarly, for the Omicron BA.1/2 wave, p_{ij}^k and q_j^k can be expressed as:

$$p_{ij}^{k} = \exp it \left(\frac{\epsilon \left(\frac{1}{2}\right)^{\frac{\Delta t}{\tau}}}{\sum_{c_{i} \in \{c_{i}\}} \gamma_{c_{i}}c_{i}} + \left(o_{nAb}^{BA1}m_{j}^{BA1} + o_{\Delta nAb}^{escape}m_{j}^{escape}\right)^{e_{j}} + \lambda e_{i}} + \right) \#(5)$$

$$q_{j}^{k} = \exp it \left(\frac{\epsilon \left(\frac{1}{2}\right)^{\frac{\Delta t}{\tau}}}{\sum_{c_{j} \in \{c_{j}\}} \gamma_{c_{j}}c_{j}} + \left(o_{nAb}^{BA1}m_{j}^{BA1} + o_{\Delta nAb}^{escape}m_{j}^{escape}\right)^{e_{j}}}{\sum_{c_{j} \in \{c_{j}\}} \gamma_{c_{j}}c_{j}} + \sum_{c_{k} \in \{c_{k}\}} \gamma_{c_{k}}c_{k}} + \beta_{s}} \right) \#(6)$$

As described before, e_i indicates individual j's prior SARS-CoV-2 infection history, with $e_i = 0$ 760 representing individual *j* remained naïve to SARS-CoV-2 at the start of Omicron BA.1/2 wave 761 while $e_i = 1$ representing individual *j* had one prior infection at the start of Omicron BA.1/2 762 763 wave and ϵ represents the effect size of the immune protection by prior infection not mediated 764 through anti-D614G nAbs (direct effect, Table 2). Δt is the elapsed time between prior infection 765 and blood draw 8 (the blood draw taken prior to the Omicron BA.1/2 wave) and τ is the waning 766 half-life of ϵ (direct effect, Table 2). Here we consider that parameter τ is shared between the Delta and Omicron wave and will be jointly estimated (described in Methods Section 4). m_j^{BA1} 767 represents the anti-BA1 nAb titer at blood draw 8 and o_{nAb}^{BA1} represents the effect size of m_i^{BA1} in 768 mediating transmission probability p_{ji}^k against the Omicron BA.1/2 wave infection (mediator 769 effect, Table 2) at blood draw 8. While m_i^{escape} represents the difference in titer from anti-770 D614G nAb to anti-BA1 nAb at blood draw 8 and $o_{\Delta nAb}^{escape}$ represents the effect size of m_j^{escape} 771 in mediating transmission probability p_{ii}^k against the Omicron BA.1/2 wave infection (mediator 772 effect, Table 2) at blood draw 8. Note that the term $o_{nAb}^{BA1}m_j^{BA1} + o_{\Delta nAb}^{escape}m_i^{escape}$ only exists 773 when $e_i = 1$. All other parameters have the same definition of the Delta wave. 774

775 $\alpha_s, \beta_s, \epsilon, \tau, o_{\Delta nAb}^{escape}, o_{nAb}^{BA1}, \{\gamma_{c_i}\}, \{\gamma_{c_k}\}$ are estimated through maximizing the likelihood 776 function *L* for each of the 100 bootstrapped realizations and bootstrap mean and confidence 777 intervals are calculated for each of the parameters.

3.2 Model 2: Sensitivity analysis considering variant-specific prior exposure for the directeffects.

780 A potential confounding factor in understanding the waning of protection through direct effects is 781 the diversity of prior SARS-CoV-2 exposures, with the dominance of D614G variant in the first 782 wave, Beta variant in the second wave, and Delta variant in the third wave (Fig. 1). The 783 effectiveness of protection may vary depending on the specific variant of prior exposure that 784 induced the immune response at play. We conducted a sensitivity analysis (Model 2) employing a 785 variant-specific model for the direct effects, which accounted for distinct types of SARS-CoV-2 786 variants conferring prior immunity, instead of considering generic a waning model. Specifically, 787 in Model 2, we considered a more complex version of Model 1, where protection from prior 788 infection depends on the type of infecting variant (i.e. prior D614G or Beta infections for the 789 Delta wave analysis, and prior D614G, Beta, or Delta infections for the Omicron wave analysis). 790 We consider waning in neutralizing titers as in Model 1, but we eliminate waning in the effect of 791 prior infection that is not captured by neutralizing titers. More specifically, for the Delta wave, p_{ii}^k and q_i^k can be expressed as: 792

$$p_{ij}^{k} = \exp it \begin{pmatrix} \epsilon^{D614G} e_{j}^{D614G} + \epsilon^{Beta} e_{j}^{Beta} + \left(\delta_{nAb}^{D614G} m_{j}^{D614G} + o_{\Delta nAb}^{waning} m_{j}^{waning}\right)^{e_{j}} + \lambda e_{i} + \\ \sum_{c_{i} \in \{c_{i}\}} \gamma_{c_{i}} c_{i} + \sum_{c_{j} \in \{c_{j}\}} \gamma_{c_{j}} c_{j} + \sum_{c_{k} \in \{c_{k}\}} \gamma_{c_{k}} c_{k} + \alpha_{s} \end{pmatrix} \# (7)$$

$$q_{j}^{k} = \exp it \begin{pmatrix} \epsilon^{D614G} e_{j}^{D614G} + \epsilon^{Beta} e_{j}^{Beta} + \left(\delta_{nAb}^{D614G} m_{j}^{D614G} + o_{\Delta nAb}^{waning} m_{j}^{waning}\right)^{e_{j}} + \\ \sum_{c_{j} \in \{c_{j}\}} \gamma_{c_{j}} c_{j} + \sum_{c_{k} \in \{c_{k}\}} \gamma_{c_{k}} c_{k} + \beta_{s} \end{pmatrix} \# (8)$$

793

Here, $e_j^{D614G(Beta)} = 1$ indicates individual *j*, prior to the Delta wave, was infected with D614G (Beta) variant. If $e_j^{D614G} = e_j^{Beta} = 0$, individual *j* was naïve at the beginning of the Delta wave. ϵ^{D614G} and ϵ^{Beta} represent the effect size of immune protection by prior D614G and Beta infection not mediated through anti-D614G nAbs, respectively.

798 For the Omicron wave, p_{ij}^k and q_j^k can be expressed as:

$$p_{ij}^{k} = \operatorname{expit}\begin{pmatrix} \epsilon^{D614G} e_{j}^{D614G} + \epsilon^{Beta} e_{j}^{Beta} + \epsilon^{Delta} e_{j}^{Delta} + \left(o_{nAb}^{BA1} m_{j}^{BA1} + o_{\Delta nAb}^{escape} m_{j}^{escape}\right)^{e_{j}} + \lambda e_{i} + \\ \sum_{c_{i} \in \{c_{i}\}} \gamma_{c_{i}} c_{i} + \sum_{c_{j} \in \{c_{j}\}} \gamma_{c_{j}} c_{j} + \sum_{c_{k} \in \{c_{k}\}} \gamma_{c_{k}} c_{k} + \alpha_{s} \end{pmatrix} \#(9)$$

$$q_j^k = \exp i \left(\begin{pmatrix} \epsilon^{D614G} e_j^{D614G} + \epsilon^{Beta} e_j^{Beta} + \epsilon^{Delta} e_j^{Delta} + \left(o_{nAb}^{BA1} m_j^{BA1} + o_{\Delta nAb}^{escape} m_j^{escape} \right)^{e_j} + \\ \sum_{c_j \in \{c_j\}} \gamma_{c_j} c_j + \sum_{c_k \in \{c_k\}} \gamma_{c_k} c_k + \beta_s \end{pmatrix} \# (10)$$

Here, $e_j^{D614G(Beta,Delta)} = 1$ indicates individual *j*, prior to the Omicron wave, was infected with D614G (Beta, Delta) variant. If $e_j^{D614G} = e_j^{Beta} = e_j^{Delta} = 0$, individual *j* was naïve at the beginning of the Omicron wave. ϵ^{D614G} , ϵ^{Beta} and ϵ^{Delta} represent the effect size of the immune protection by prior D614G, Beta and Delta infection not mediated through anti-D614G nAbs, respectively.

Additionally, similarly to Model 1, both the Delta and Omicron wave infections were ascertained
by serology for Model 2. All other settings of Model 2 were kept the same as Model 1. The
results of the Model 2 are presented in Extended Data Table 2.

Our analysis revealed that for both the Delta and Omicron waves, more recent variants conferred stronger protection than earlier variants, albeit with overlapping confidence intervals (Extended Data Table 2). This temporal trend aligns with the expectations of the waning model. Both waning and variant-specific immunity may modulate the direct effects of prior immunity; however, our study lacked sufficient statistical power to jointly estimate the relative contributions of these two factors. Full estimates of this sensitivity analyses are presented in Extended Data Table 2.

814

815 3.3 Model 3: Sensitivity analysis with Delta wave infections ascertained by PCR and/or 816 serology.

817 For Model 1, both the Delta and Omicron wave infection outcomes were inferred using the 818 kinetics of anti-nucleocapsid antibodies from longitudinal serologic sampling, as detailed in previously published studies of the PHIRST-C cohort ^{30,32}. This approach for inferring infections 819 820 based on serology was calibrated against virological evidence of infection during the Delta wave, 821 established through twice-weekly rRT-PCR tests regardless of symptom presentation. However, 822 it should be noted that this calibration did not achieve perfect concordance; the serology 823 approach demonstrated 93% sensitivity and 89% specificity when compared to infections identified by rRT-PCR tests ³⁰. To address the uncertainties arising from the imperfect 824

concordance between the two approaches for ascertaining infections, we conducted a sensitivity analysis (Model 3) for the Delta wave, where we considered infections based on rRT-PCR positivity and/or anti-nucleocapsid antibody serology. We identified an additional 17 infections during the Delta wave through this more sensitive infection ascertainment approach, bringing the total number of Delta wave infections to 290. All other settings of Model 3 were kept the same as Model 1. The results of the Model 3 are presented in Extended Data Table 3.

Notably, estimates of the direct and indirect effects of the mediation analysis were comparable
between this sensitivity analysis and the main analysis (compare Extended Data Table 3 to Table
1). These findings provide support for the utilization of anti-nucleocapsid serology to ascertain
Omicron BA.1/2 wave infections in the studied cohorts, in a period where twice-weekly rRTPCR testing was not available and confirms the robustness of our CoP analyses.

836

837 **3.4** Model 4: D614G spike binding antibodies as mediators of protection.

838 We conducted sensitivity analysis (Model 4) to explore the role of D614G spike binding 839 antibodies (referred to as bAb hereafter), as potential correlates of protection for both Delta and 840 Omicron infections. Employing an in-house enzyme-linked immunosorbent assay (ELISA), we 841 quantified the level of D614G spike bAb based by measuring absorbance at 450nm at an optical 842 density (OD) at peak levels and BD5 (DB8) for the Delta (Omicron) wave analysis (Extended 843 Data Fig. 3). The reduction in binding antibody levels from peak (ΔbAb^W) was determined as the 844 difference between OD values at peak and BD5 (BD8) for the Delta (Omicron) wave (Extended 845 Data Fig. 3).

846 Model 4 builds on Model 2 but replaces nAb titers with D614G spiking binding ELISA readouts 847 as mediators of protection, in order to compare the protection afforded by neutralizing vs binding 848 antibodies. More specifically, for the Delta wave, p_{ij}^k and q_j^k can be expressed as:

$$p_{ij}^{k} = \expit \begin{pmatrix} \epsilon^{D614G} e_{j}^{D614G} + \epsilon^{Beta} e_{j}^{Beta} + \left(\delta_{bAb}^{D614G} m_{j}^{D614G} + o_{\Delta bAb}^{waning} m_{j}^{waning}\right)^{e_{j}} + \lambda e_{i} + \\ \sum_{c_{i} \in \{c_{i}\}} \gamma_{c_{i}} c_{i} + \sum_{c_{j} \in \{c_{j}\}} \gamma_{c_{j}} c_{j} + \sum_{c_{k} \in \{c_{k}\}} \gamma_{c_{k}} c_{k} + \alpha_{s} \end{pmatrix} \#(11)$$

$$q_{j}^{k} = \exp i \left(\begin{array}{c} \epsilon^{D614G} e_{j}^{D614G} + \epsilon^{Beta} e_{j}^{Beta} + \left(\delta_{bAb}^{D614G} m_{j}^{D614G} + o_{\Delta bAb}^{waning} m_{j}^{waning} \right)^{e_{j}} + \\ \sum_{c_{j} \in \{c_{j}\}} \gamma_{c_{j}} c_{j} + \sum_{c_{k} \in \{c_{k}\}} \gamma_{c_{k}} c_{k} + \beta_{s} \end{array} \right) \# (12)$$

849

Here, m_j^{D614G} represents the D614G spike binding antibodies ELISA readout at blood draw 5 and δ_{bAb}^{D614G} represents the effect size of m_j^{D614G} in mediating transmission probability p_{ij}^k against the Delta wave infection at blood draw 5. Further, m_j^{waning} represents the drop from peak D614G spike binding antibodies readout prior to blood draw 5 (measured as the highest D614G spike binding Ab titer level among the first 5 blood draws) to that at blood draw 5 and v_{AbAb}^{waning} represents the effect size of m_j^{waning} in mediating transmission probability p_{ji}^k against the Delta wave infection at blood draw 5.

857 For the Omicron wave, p_{ij}^k and q_j^k can be expressed as:

$$p_{ij}^{k} = \exp it \begin{pmatrix} \epsilon^{D614G} e_{j}^{D614G} + \epsilon^{Beta} e_{j}^{Beta} + \epsilon^{Delta} e_{j}^{Delta} + \\ \left(\delta_{bAb}^{D614G} m_{j}^{D614G} + o_{\Delta bAb}^{waning} m_{j}^{waning} \right)^{e_{j}} + \lambda e_{i} + \\ \sum_{c_{i} \in \{c_{i}\}} \gamma_{c_{i}} c_{i} + \sum_{c_{j} \in \{c_{j}\}} \gamma_{c_{j}} c_{j} + \sum_{c_{k} \in \{c_{k}\}} \gamma_{c_{k}} c_{k} + \alpha_{s} \end{pmatrix} \# (13)$$

$$q_j^k = \operatorname{expit}\begin{pmatrix} \epsilon^{D614G} e_j^{D614G} + \epsilon^{Beta} e_j^{Beta} + \epsilon^{Delta} e_j^{Delta} + \\ \left(\delta_{bAb}^{D614G} m_j^{D614G} + o_{\Delta bAb}^{waning} m_j^{waning} \right)^{e_j} + \\ \sum_{c_j \in \{c_j\}} \gamma_{c_j} c_j + \sum_{c_k \in \{c_k\}} \gamma_{c_k} c_k + \beta_s \end{pmatrix} \#(14)$$

Here, m_i^{D614G} represents the D614G spike binding antibodies ELISA readout at blood draw 8 858 and δ_{bAb}^{D614G} represents the effect size of m_j^{D614G} in mediating transmission probability p_{ij}^k 859 against the Omicron wave infection at blood draw 8. While m_j^{waning} represents the drop from 860 peak D614G spike binding antibodies readout prior to blood draw 8 (measured as the highest 861 862 D614G spike binding Ab titer level among the first 8 blood draws) to that at blood draw 8 and $o_{\Delta bAb}^{waning}$ represents the effect size of m_i^{waning} in mediating transmission probability p_{ji}^k against 863 864 the Omicron wave infection at blood draw 8. All other settings of Model 4 were kept the same as 865 Model 2. The results of the Model 4 are presented in Extended Data Table 4.

866 We found that binding antibody levels at BD5 (BD8) correlate with protection against Delta 867 (Omicron) wave infections: the risk of infection decreased by 74% (95% CI 41% - 88%) and 40% 868 (95% CI 33% – 54%) per unit increase in OD value for the Delta and Omicron wave analyses, 869 respectively. Conversely, the decline in bAbs from peak levels to BD5/BD8 (ΔbAb^W) 870 demonstrated no contribution to the overall protection, with risk reduction per 10-fold increase: -871 2% (95%CI: -91% - 55%) for Delta wave infections and -2% (95%CI: -87% - 55%) for 872 Omicron wave infections. These findings underscore the correspondence between waning of 873 binding antibodies and a waning of protection. Furthermore, our estimations indicate that the 874 proportion of protection conferred through D614G spike bAbs at BD5 is 35% (95%CI: 32% – 875 38%) against Delta wave infections, a figure comparable estimation based on anti-D614G nAbs 876 (37%, 95%CI: 34% – 40%, Extended Data Table 4). Notably, D614G spike bAbs at BD8 877 accounted for 27% (95% CI: 25% - 29%) of protection against Omicron wave infection, 878 representing a larger proportion compared to anti-BA.1 nAbs (11%, 95%CI: 9% - 12%, 879 Extended Data Table 4).

880

4. Transmission chains imputation and parameters estimation based on an Expectationmaximization (EM) algorithm.

883 Here we describe the process to fit the models described in Section 3 to the household infection 884 data. The serologic data available for the Delta and Omicron only provides information on the 885 total number of infections within the household between two blood draws collected before and 886 after the SARS-CoV-2 wave. The data does not provide the details of the transmission chains 887 within the household, the order of infections among infected individuals, nor the infection dates. 888 To account for the uncertainties of the transmission tree structure within households given only 889 the total number of infections, we enumerate and reconstruct all possible transmission chains 890 among the infected individuals, where each infected individual may have been infected by members of their own household or the general community. Supplementary Fig. 1 illustrates all 891 892 16 possible configurations of transmission chains for a household with 3 infected individuals. We 893 limited our analysis to households with no more than 6 infected individuals, as the possible 894 configurations of transmission chains among 6 infected individuals already reaches 16,807. 895 Enumeration of all possible transmission chain configurations would be computationally

intractable for households with more than 6 infected individuals. Additionally, the probability of each possible transmission chain depends on the parameter estimates of the transmission model described in Methods Section 3. To address the statistical uncertainties due to unresolved transmission chains (which would affect the statistical confidence of mediation analysis detailed in the prior section), we jointly fit the household transmission model and impute the topological structure of the transmission trees. We use an EM algorithm, as described below.

902 To resolve who infected whom within the household in a probabilistic manner, we considered an 903 EM algorithm that iteratively estimates the transmission model parameters α_s , β_s , ϵ , τ , 904 $\delta_{nAb}^{D614G/BA1}$, $o_{\Delta nAb}^{waning/escape}$, { γ_{c_i} }, { γ_{c_j} }, { γ_{c_k} } through maximizing the likelihood function *L* as 905 described in Equation (1) in the previous section then updates the imputed probability of each 906 transmission tree configuration within each household based on the fitted transmission model. 907 The process is as follows:

- 908 (1) Initial imputation of the household transmission trees with equal sampling probability for
 909 all configurations: For each household, we randomly sample one transmission tree with
 910 equal probability among all transmission tree configurations that are compatible with the
 911 number of infections. We iterate through all households so that each household has a
 912 simulated transmission tree. We then repeat the imputation 1000 times to obtain 1000
 913 realizations of each household's transmission tree.
- 914 (2) Maximization step: We consider the waning parameter τ a hyper-parameter (nonlinear 915 term in equations (3-6), cannot be estimated by logistic regression). For a fixed value of τ , 916 for each of the 1000 realizations of the simulated household transmission chains, we estimate transmission model parameters α_s , β_s , ϵ , $\delta_{nAb}^{D614G/BA1}$, $o_{\Delta nAb}^{waning/escape}$, $\{\gamma_{c_i}\}$, 917 $\{\gamma_{c_i}\}, \{\gamma_{c_k}\}$ through maximizing the likelihood function *L* described in Equation (1). The 918 919 maximization of the likelihood function is achieved through fitting a logistic regression 920 of the infection/exposure outcomes for all participants using R package "brglm" (version 0.7.2). We then pool the estimates from the 1000 realizations using the "pool" function in 921 the R package "mice" (version 3.16.0). The full likelihood of the combined Delta and 922 Omicron waves fitting in this EM step m can be expressed as $L_m(\tau) = L_m^{Delta}(\tau) \times$ 923 $L_m^{Omicron}(\tau)$ 924

925 (3) Expectation step: for a fixed value of hyper-parameter τ , based on the pooled estimates of the transmission model parameters α_s , β_s , ϵ , $\delta_{nAb}^{D614G/BA1}$, $o_{\Delta nAb}^{waning/escape}$, $\{\gamma_{c_i}\}, \{\gamma_{c_j}\}, \{\gamma_$ 926 $\{\gamma_{c_k}\}$, we calculate the likelihood all configurations of transmission chains within each 927 928 household based on Equation (2). We use these configuration-specific likelihoods to 929 resample transmission chains: For each household, we randomly sample one transmission 930 tree among all transmission tree configurations with probability proportional to 931 transmission tree likelihood prescribed in Equation (2), given the parameters estimated by 932 the most recent maximization step. We iterate through all households so that each 933 household is assigned one simulated transmission tree. We repeat the process 1000 times 934 to obtain 1000 realizations of the household transmission trees.

- 935 (4) For each of the fixed value of hyper-parameter τ over a plausible range (30 - 500 days), we iterate over the EM steps (2) and (3) until $L_m(\tau)$ converge to the maximum value of 936 937 the EM algorithm. We scan through the values of τ from 30 to 500 days at 10 days step. 938 The EM algorithm convergence curve is shown in Supplementary Fig. 2 for each of the τ 939 values. The EM algorithm converges at step 50, irrespective of the value of τ . The 940 marginal likelihood of the model at τ , $L(\tau)$ is estimated by taking the average of $L_m(\tau)$ 941 for EM steps 50 through 100. Supplementary Fig. 3 shows the log of the likelihood $L(\tau)$ 942 as a function of τ , based on a spline interpolation. The point estimate of τ is taken from the maximum of $\log(L(\tau))$ while the 95% confidence interval is estimated by finding τ 943 944 values with log-likelihood value at the maximum minus 1.92 (Supplementary Fig. 3).
- 945 (5) We then take the best estimate of hyper-parameter τ and repeat the EM algorithm till 946 convergence to estimate transmission model parameters α_s , β_s , ϵ , $\delta_{nAb}^{D614G/BA1}$, 947 $o_{\Delta nAb}^{waning/escape}, \{\gamma_{c_i}\}, \{\gamma_{c_k}\}$ as show in Table 2. Same EM algorithm were applied to 948 Model 2-4 for the sensitivity analysis as well.
- 949 The "treatment effect" by prior infection is estimated by simulating from the best-fit model. We 950 first sample 1000 realizations of the imputed household transmission trees, with imputation 951 probability proportional to the best estimates of transmission model using the EM algorithm and 952 hyper-parameter τ . For each of the 1000 realizations, we focus on the subset of individuals who 953 had one prior SARS-CoV-2 infection, denoted as $S_i = \{j | e_i = 1\}$). We use the fitted

954 transmission model to predict the probability of infection (i.e. $P_j = p_{ij}^k$ or q_j^k , with) of these 955 non-naïve subsets under three scenarios:

- 956 a. Scenario 1: the probability of infection estimated with predictors as reported in 957 the data, denoted as P_i^{obs} .
- 958 b. Scenario 2: a counterfactual scenario where the probability of infection is 959 estimated with predictor $e_j = 0$ (i.e. a counterfactual naïve individual) whereas all 960 other covariates (confounders) are the same as observed, removing both direct and 961 mediator effects. We denote the infection probability in this counterfactual 962 scenario as $P_i^{\text{counterfactual}} (e_i = 0)$.
- 963 c. Scenario 3: a counterfactual scenario where the probability of infection is 964 estimated with predictor $e_j = 1$, but setting $m_{nAb}^{BA1} = 0$ (or $m_{nAb}^{D614G} = 0$), 965 effectively removing the mediator effect of nAb on preventing transmission, but 966 keeping the direct effect. We denote the infection probability in this counterfactual 967 scenario as $P_j^{\text{counterfactual}} (e_j = 1; m_{nAb} = 0)$.

We then calculate the total protection conferred by prior infection as the population average of $P_j^{\text{counterfactual}}(e_j = 0)/P_j^{obs}$, based on bootstrap resampling with replacement (maintaining the same number of observations) of each of the 1000 realizations of the household transmission chains. Point estimates and 95% confidence intervals are based on the median and 95% quantiles of 1000 realizations' estimates.

- 973 Similarly, we calculate the proportion of protection mediated by nAbs as the population average 974 of $1 - \frac{P_j^{\text{counterfactual}}(e_j=1; m_{nAb}=0)/P_j^{obs}}{P_i^{\text{counterfactual}}(e_j=0)/P_j^{obs}}$. We use the same bootstrapping approach as for total
- 975 protection. $(e_j 0)/r_j$

977 Data availability

978 Aggregate reproduce figures available Zenodo (DOI: data to the are at 979 10.5281/zenodo.11375487). Individual-level data cannot be publicly shared because of ethical 980 restrictions and the potential for identifying included individuals. Accessing individual 981 participant data and a data dictionary defining each field in the dataset would require provision 982 of protocol and ethics approval for the proposed use. To request individual participant data 983 access, please submit a proposal to C.C. who will respond within 1 month of request. Upon 984 approval, data can be made available through a data sharing agreement.

985 Code availability

- 986 Code to reproduce the figures, using python version 3.8.11 and scipy version 1.7.1 is available at
- 987 Zenodo (DOI: <u>10.5281/zenodo.11375487</u>).

988 Extended Data Figures:

989



Extended Data Fig. 1: Flowchart of participants included in the Delta-wave subgroup analysis. Grey boxes
 represent participants excluded from the Delta-wave subgroup analysis.

993 *Based on a previously published study ³⁰.

[†]Household with more than 6 infected individuals would be computationally intractable to track all possible
transmission chain configurations (Material and Methods Section 3).



997

Extended Data Fig. 2: Flowchart of participants included in the Omicron-wave subgroup analysis. Grey boxes
 represent participants excluded from the Omicron-wave subgroup analysis.

....

1000 *Based on a previously published study ³⁰.

1001 [†]Household with more than 6 infected individuals would be computationally intractable to track all possible

transmission chain configurations (Material and Methods Section 3).



1004

1005 Extended Data Fig. 3: D614G spike binding antibody (bAb) level for the Delta wave and the Omicron wave 1006 analysis. a, for Delta wave subgroup, the distribution of the peak bAb level to BD5 (light blue dots) and the D614G 1007 spike bAb level at BD5 (dark blue dots), among individuals who had one prior SARS-CoV-2 infection before blood 1008 draw 5. Each dot represents one individual, with two measurements of the same individual connected through a gray 1009 line. OD: absorbance at 450 nm, measured in optical density; \overline{OD} : the average of OD; $\overline{\Delta OD}$: the average drop of OD. 1010 **b**, for Delta wave subgroup, the distribution of the peak D614G spike bAb up to BD5, stratified by individuals who 1011 were infected during the Delta wave (solid bar) vs those who were not infected (dashed bar). Independent samples t-1012 test (two-sided) is used to determine the statistical significance (anti reported on the legend) of difference between 1013 the \overline{OD} of the two groups. c, same as b but for D614G spike bAb level at BD5. d, same as b but for ΔbAb^{W} . e, for 1014 Omicron wave subgroup, the distribution of the peak bAb level to BD8 (light red dots) and the D614G spike bAb 1015 level at BD8 (dark red dots), among individuals who had one prior SARS-CoV-2 infection before BD8. Each dot 1016 represents one individual, with two measurements of the same individual connected through a gray line. f, for the 1017 Omicron wave subgroup, the distribution of the D614G spike bAb level at BD8, stratified by individuals who were 1018 infected during the Omicron wave (solid bar) vs those who were not infected (dashed bar). Independent samples t-1019 test (two-sided) is used to determine the statistical significance (p-value reported on the legend) of difference 1020 between the \overline{ODs} of the two groups, g, same as f but for D614G spike bAb level at BD8, d, same as f but for ΔbAb^W .

1022 Extended Data Tables:

1023 Extended Data Table 1: Positivity rate of different serologic assays by the variant type of prior exposure for

1024 the Delta and Omicron wave subgroup.

Delta wave subgroup				
Seropositivity	Prior D614G infection	Prior Beta infection	Prior Delta exposure	
Anti-nucleocapsid assay were positive in at least one of the first 5 blood draws	109/113 (97%)	133/140 (95%)	_	
Anti-nucleocapsid assay were positive at BD5	104/113 (92%)	129/140 (92%)	_	
Anti-D614G nAb assay were positive for peak nAb response.	87/113 (77%)	60/140 (43%)		
Anti-D614G nAb were positive for nAb response at BD5	81/113 (72%)	59/140 (42%)	_	
Omicron wave subgroup				
Seropositivity	Prior D614G exposure	Prior Beta exposure	Prior Delta exposure	
Anti-nucleocapsid assay were positive in at least one of the first 8 blood draws	60/61 (98%)	116/120 (97%)	160/161 (99%)	
Anti-nucleocapsid assay were positive at BD8	58/61 (95%)	108/120 (90%)	159/161 (99%)	
Anti-D614G nAb were positive for nAb response at BD8	57/61 (93%)	71/120 (59%)	140/161 (87%)	
Anti-BA.1 nAb were positive for nAb response at BD8	29/61 (48%)	36/120 (30%)	50/161 (31%)	

- 1026 Extended Data Table 2: Mediation analysis for nAbs as CoPs against serologically ascertained Delta and
- 1027 Omicron wave infections, with a variant-specific model for direct effect. Average and 95% CIs are provided for
- 1028 each of the model parameters. ΔnAb^{W} : the quantity of anti-D614G nAbs waned from peak level to that at BD5.
- 1029 ΔnAb^{E} : the quantity of antibodies that can neutralize D614G but fail to neutralize Omicron BA.1 at BD8 due to
- 1030 Omicron's immune escape.

Wave		Delta	Omicron	
Protection against reinfection	Direct effect (Protection absent of nAbs)	Prior D614G exposure (odds ratio, absent of waning)	0.76 (0.36, 1.61)	1.23 (0.63, 2.38)
		Prior Beta exposure (odds ratio, absent of waning)	0.47 (0.30, 0.76)	0.78 (0.50, 1.21)
		Prior Delta exposure (odds ratio, absent of waning)	_	0.47 (0.29, 0.76)
	Mediators effect (Protection from nAbs)	Anti-D614G nAb (odds ratio, per 10-fold increase)	0.59 (0.43, 0.83)	_
		ΔnAb^{W} (odds ratio, per 10-fold increase)	1.00 (0.72, 1.39)	_
		Anti-BA.1 nAb (odds ratio, per 10-fold increase)	_	0.73 (0.56, 0.95)
		ΔnAb^E (odds ratio, per 10-fold increase)	_	0.94 (0.76, 1.15)
	Total protection (relative risk compared to naïve individuals)		0.40 (0.38, 0.42)	0.70 (0.68, 0.72)
	Proportion of protection mediated by nAbs		37% (34%, 40%)	11% (9%, 12%)
Protection against onward transmission (Odds ratio compared to naïve individuals)		0.20 (0.05, 0.72)	1.11 (0.62, 2.00)	

1031

- 1033 Extended Data Table 3: Mediation analysis for nAbs as CoPs against Delta (ascertained by both serology and
- 1034 PCR) and Omicron wave infections, with a waning model for direct effect. Average and 95% CIs are provided
- 1035 for each of the model parameters. ΔnAb^{W} : the quantity of anti-D614G nAbs waned from peak level to that at BD5.
- **1036** ΔnAb^{E} : the quantity of antibodies that can neutralize D614G but fail to neutralize Omicron BA.1 at BD8 due to
- 1037 Omicron's immune escape.

Wave		Delta	Omicron	
Protection against reinfection	Direct effect (Protection absent of nAbs)	Effect size (odds ratio, absent of waning)	0.34 (0.17, 0.64)	0.29 (0.17, 0.51)
		Waning half-life (days)	128 (77, 261)	
	Mediators effect (Protection from nAbs)	Anti-D614G nAb (odds ratio, per 10-fold increase)	0.65 (0.49, 0.86)	_
		ΔnAb^W (odds ratio, per 10-fold increase)	1.02 (0.78, 1.36)	_
		Anti-Omicron BA.1 nAb (odds ratio, per 10-fold increase)	_	0.73 (0.56, 0.95)
		ΔnAb^E (odds ratio, per 10-fold increase)	_	1.01 (0.84, 1.21)
	(relati	Total protection ve risk compared to naïve individuals)	0.41 (0.40, 0.43)	0.62 (0.61, 0.64)
	Proportion of protection mediated by nAbs		33% (30%, 35%)	11% (9%, 12%)
Protection against onward transmission (Odds ratio compared to naïve individuals)		0.23 (0.08, 0.71)	1.19 (0.66, 2.13)	

1038

- 1040 Extended Data Table 4: Mediation analysis for D614G spike binding antibody as CoPs against serologically
- 1041 ascertained Delta and Omicron wave infections, with a variant-specific model for direct effect. Average and 95%
- 1042 CIs are provided for each of the model parameters. ΔbAb^{W} : the quantity of D614G spike binding antibodies waned 1043 from peak level to that at BD5 for Delta (at BD8 for Omicron).

	Protection against reinfection		Delta (serology)	Omicron (serology)
	Direct effect (Protection absent of nAbs)	Prior D614G exposure (odds ratio, absent of waning)	0.60 (0.24, 1.48)	1.38 (0.67, 2.84)
		Prior Beta exposure (odds ratio, absent of waning)	0.51 (0.32, 0.83)	0.91 (0.58, 1.45)
		Prior Delta exposure (odds ratio, absent of waning)	-	0.61 (0.38, 0.97)
	Mediators effect (Protection from nAbs)	D614G binding Ab (odds ratio, per 10-unit increase)	0.26 (0.12, 0.59)	0.60 (0.46, 0.77)
		ΔbAb^W (odds ratio, per 10-unit increase)	1.02 (0.55, 1.91)	1.02 (0.55, 1.87)
	Total protection (relative risk compared to naïve individuals) Proportion of protection mediated by spike binding Ab		0.40 (0.38, 0.42)	0.65 (0.63, 0.67)
			35% (32%, 38%)	27% (25%, 29%)
	Protecti (Odd	ion against onward transmission Is ratio compared to naïve individuals)	0.22 (0.06, 0.74)	1.18 (0.65, 2.13)

1044

1046 Supplementary Information



1047

1048 Supplementary Fig. 1: Visualization of all 16 possible transmission chains within a household of 3 infected1049 individuals.



1052 Supplementary Fig. 2: The log-likelihood of the transmission model fit, as a function of the EM steps.

1053

1054



1055

Supplementary Fig. 3: The profile log-likelihood of the transmission model over hyper-parameter of waning
 half-life. Solid vertical line indicates the waning half-life corresponding to maximum of the profile likelihood.

1058 Dashed horizontal line represent 1.92 below the maximum profile likelihood.